Adverse events912

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 912

Type	Event	Organ system	Group	Affected	At risk
other	Neutropenia	Blood and lymphatic system disorders	Arm A: Obinutuzumab in Combination With Chlorambucil	76	169
other	Neutropenia	Blood and lymphatic system disorders	Arm B: Acalabrutinib in Combination With Obinutuzumab	56	178
other	Neutropenia	Blood and lymphatic system disorders	Arm C: Acalabrutinib Monotherapy	19	179
other	Neutropenia	Blood and lymphatic system disorders	Arm A Cross-over: Obinutuzumab+Chlorambucil Crossover to Acalabrutinib Monotherapy	1	45
other	Thrombocytopenia	Blood and lymphatic system disorders	Arm A: Obinutuzumab in Combination With Chlorambucil	24	169
other	Thrombocytopenia	Blood and lymphatic system disorders	Arm B: Acalabrutinib in Combination With Obinutuzumab	23	178
other	Thrombocytopenia	Blood and lymphatic system disorders	Arm C: Acalabrutinib Monotherapy	13	179
other	Thrombocytopenia	Blood and lymphatic system disorders	Arm A Cross-over: Obinutuzumab+Chlorambucil Crossover to Acalabrutinib Monotherapy	3	45
other	Anaemia	Blood and lymphatic system disorders	Arm A: Obinutuzumab in Combination With Chlorambucil	20	169
other	Anaemia	Blood and lymphatic system disorders	Arm B: Acalabrutinib in Combination With Obinutuzumab	21	178
other	Anaemia	Blood and lymphatic system disorders	Arm C: Acalabrutinib Monotherapy	25	179
other	Anaemia	Blood and lymphatic system disorders	Arm A Cross-over: Obinutuzumab+Chlorambucil Crossover to Acalabrutinib Monotherapy	0	45
other	Diarrhoea	Gastrointestinal disorders	Arm A: Obinutuzumab in Combination With Chlorambucil	36	169
other	Diarrhoea	Gastrointestinal disorders	Arm B: Acalabrutinib in Combination With Obinutuzumab	69	178
other	Diarrhoea	Gastrointestinal disorders	Arm C: Acalabrutinib Monotherapy	62	179
other	Diarrhoea	Gastrointestinal disorders	Arm A Cross-over: Obinutuzumab+Chlorambucil Crossover to Acalabrutinib Monotherapy	8	45
other	Nausea	Gastrointestinal disorders	Arm A: Obinutuzumab in Combination With Chlorambucil	53	169
other	Nausea	Gastrointestinal disorders	Arm B: Acalabrutinib in Combination With Obinutuzumab	36	178
other	Nausea	Gastrointestinal disorders	Arm C: Acalabrutinib Monotherapy	40	179
other	Nausea	Gastrointestinal disorders	Arm A Cross-over: Obinutuzumab+Chlorambucil Crossover to Acalabrutinib Monotherapy	9	45

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02475681/events

API reference For AI assistants

Adverse events912

Sources 3

Read this list from software.